亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.

乳腺癌 癌症 激素受体 表皮生长因子受体 人表皮生长因子受体2 芳香化酶抑制剂 阿那曲唑
作者
Verin Lertjanyakun,Nathorn Chaiyakunapruk,Susumu Kunisawa,Yuichi Imanaka
出处
期刊:PharmacoEconomics [Adis, Springer Healthcare]
卷期号:36 (9): 1113-1124 被引量:2
标识
DOI:10.1007/s40273-018-0660-3
摘要

Exemestane (EXE), exemestane + everolimus (EXE + EVE), toremifene (TOR), and fulvestrant (FUL) are second-line endocrine therapies for postmenopausal hormone receptor–positive (HR +)/human epidermal growth factor receptor 2–negative (HER2 −) metastatic breast cancer (mBC) in Japan. Although the efficacy of these therapies has been shown in recent studies, cost-effectiveness has not yet been determined in Japan. This study aimed to examine the cost-effectiveness of second-line endocrine therapies for the treatment of postmenopausal women with HR + and HER2 − mBC. A Markov model was developed to analyze the cost-effectiveness of the therapies over a 15-year time horizon from a public healthcare payer’s perspective. The efficacy and utility parameters were determined via a systematic search of the literature. Direct medical care costs were used. A discount rate of 2% was applied for costs and outcomes. Subgroup analysis was performed for non-visceral metastasis. A series of sensitivity analyses, including probabilistic sensitivity analysis (PSA) and threshold analysis were performed. Base-case analyses estimated incremental cost-effectiveness ratios (ICERs) of 3 million and 6 million Japanese yen (JPY)/quality-adjusted life year (QALY) gained for TOR and FUL 500 mg relative to EXE, respectively. FUL 250 mg and EXE + EVE were dominated. The overall survival (OS) highly influenced the ICER. With a willingness-to-pay (WTP) threshold of 5 million JPY/QALY, the probability of TOR being cost-effective was the highest. Subgroup analysis in non-visceral metastasis revealed 0.4 and 10% reduction in ICER from the base-case results of FUL5 500 mg versus EXE and TOR versus EXE, respectively, while threshold analysis indicated EVE and FUL prices should be reduced 73 and 30%, respectively. As a second-line therapy for postmenopausal women with HR +/HER2 − mBC, TOR may be cost-effective relative to other alternatives and seems to be the most favorable choice, based on a WTP threshold of 5 million JPY/QALY. FUL 250 mg is expected to be as costly and effective as EXE. The cost-effectiveness of EXE + EVE and FUL 500 mg could be improved by a large price reduction. However, the results are highly sensitive to the hazard ratio of OS. Policy makers should carefully interpret and utilize these findings.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
俏皮含双完成签到,获得积分10
2秒前
baidi发布了新的文献求助10
2秒前
陈不沉完成签到 ,获得积分10
2秒前
Sunnpy发布了新的文献求助80
4秒前
清爽的口红完成签到,获得积分10
7秒前
future完成签到,获得积分10
8秒前
11秒前
清新的雨文完成签到,获得积分10
12秒前
无问西东完成签到 ,获得积分10
14秒前
17秒前
baidi完成签到,获得积分20
20秒前
GAOjiale完成签到 ,获得积分10
21秒前
28秒前
35秒前
冷酷紫烟完成签到,获得积分10
37秒前
47秒前
超帅的香露完成签到,获得积分10
48秒前
MeiyanZou完成签到,获得积分10
52秒前
59秒前
英姑的应助被xinxin采纳,获得10
1分钟前
1分钟前
天天快乐的应助被科研通管家采纳,获得10
1分钟前
leev完成签到,获得积分10
1分钟前
1分钟前
xinxin发布了新的文献求助10
1分钟前
楚楚完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
进击的小人完成签到,获得积分10
1分钟前
快乐星球在逃居民完成签到,获得积分10
1分钟前
危机的奄完成签到,获得积分10
1分钟前
温柔的香岚完成签到,获得积分10
1分钟前
1分钟前
真实的瑾瑜完成签到 ,获得积分10
1分钟前
11完成签到,获得积分10
1分钟前
2分钟前
hangfengzi完成签到,获得积分10
2分钟前
苏景烟发布了新的文献求助20
2分钟前
fantasy的应助被晚霞跌落星河采纳,获得10
2分钟前
fantasy的应助被晚霞跌落星河采纳,获得10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179810
求助须知:如何正确求助?哪些是违规求助? 9570000
关于积分的说明 21808070
捐赠科研通 7775430
什么是DOI,文献DOI怎么找? 3433157
关于科研通互助平台的介绍 2557220
邀请新用户注册赠送积分活动 2478832